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S1 
STRUCTURE, DYNAMICS AND ENERGETICS IN
ANTISENSE AND ANTIGENE OLIGONUCLEOTIDES 
Andrew N. Lane, James Graham Brown Cancer Center,
University of Louisville, KY, USA. 
The development of anticancer drugs is a complex process involving
many, often competing, factors. We have been working on the structural
and energetic analysis of targeting both DNA and mRNA by oligonuc-
leotides. Some of the major problems are ones of thermodynamic and
biochemical stability, uptake and intracellular delivery. In a long-standing
collaboration with T. Brown (University of Southampton) we have
examined the structures, thermodynamics and dynamics of several DNA.
RNA hybrid duplexes (antisense), and the corresponding DNA and RNA
properties are not intuitively obvious, and require a somewhat different 
way of dealing with the problem (1). In particular the roles of conforma-
tional flexibility and hydration will be emphasized. The stabilisation by
particular base modifications has also been characterised. In parallel we
have also been investigating the thermodynamic stability and conforma-
tions of parallel triple helices (antigene), and the influence of modificat-
ions on these properties. The structural and thermodynamics analysis has
established some important ground rules for stabilizing these structures
(2), which has lead to a new generation of modified nucleotides that have
greatly enhanced biochemical and thermodynamic stability. The results
underline the importance of collaborations between structural biologists,
biophysicists, computational biologists and synthetic chemists.
However, some possibilities for improving the efficacy of antigene
approaches will be discussed, and strategies for improving oligonuc-
leotide design based on structural data. 
(1) Gyi et al. (1998) Biochemistry  37, 73-80
(2) Asensio et al. (1999) Structure 7, 1-11 
duplexes. The origin of the stability of the duplexes, and their solution
There are some important cell biological problems remaining that have
not yielded to direct conformational and thermodynamic analysis.
S2
ENERGETICS AND BIOPHYSICS OF DRUG BINDING FOR
CANCER AGENTS – “SMART DRUG DESIGN”
Terry C. Jenkins, YCR Laboratory of Drug Design, Tom Connors
Cancer Research Centre, University of Bradford, West Yorkshire
BD7 1DP, UK
Rational drug development using template-directed design
approaches offers an opportunity to develop novel agents for key
biomolecular targets in tumour cells. In this strategy, structural
methods are augmented by molecular modelling and biophysical
assays, so that it possible to fine-tune a small molecule to achieve
exquisite potency. Using this ‘molecular tailoring’ approach, a
novel class of potent DNA cross-linking agents bearing
N2(guanine)-alkylating pyrrolobenzodiazepine (PBD) sub-units
has been evolved from otherwise inert bis-(amidinophenyl) ethers,
such as propamidine and pentamidine. The latter drugs act as
minor groove-binding agents for double-stranded DNA (A/T-
preferential binding), and their molecular platform is eminently
suitable as a delivery vehicle for modification (mutation) or
attachment of suitable alkylating war-heads. Early success from
this approach was realised with DSB-120, the first reported PBD
dimer (with Profs. DE Thurston and JA Hartley, and Spirogen
colleagues). This compound shows in vitro potency (e.g. IC50 =
0.25 µM for human K562 leukaemia) and efficient interstrand
DNA cross-linking (C50% = 55 nM towards plasmid pBR322) for
5'-GATC targets in DNA, but lacked in vivo efficacy. Further
manipulation of the PBD residues resulted in SJG-136, where both
cytotoxic potency and reactivity are enhanced (IC50 = 0.04 µM for
K562; C50% = 45 nM), and this dimer has now been selected for
clinical trial. The design, evaluation and evolution process will be
discussed, together with recent (i.e. hotter!) developments for this
remarkable class of anti-tumour agent. 
S3 
TOPOISOMERASE I AND CANCER CHEMOTHERAPY : 
NEW INHIBITORS, NOVEL CONCEPTS 
Christian Bailly, INSERM U-524 and Centre Oscar Lambret, 
Lille, France (bailly@lille.inserm.fr) 
Fifteen years of efforts in targeting topoisomerase I for the
discovery of anticancer agents have lead to the identification of
several families of compounds capable of stabilizing DNA-
topoisomerase I covalent complexes. The lead series is the
camptothecin family with two drugs, topotecan and irinotecan,
approved for cancer treatment and several second (e.g. lurtotecan,
exatecan) and third (e.g. diflomotecan) generations of
camptothecin analogs currently in clinical trials (1). However,
apart from the camptothecins, only a few topoisomerase I poisons
have reached phase I clinical trials. Promising results have been
reported with glycosyl indolocarbazoles (2) but so far there is still
no non-CPT topoisomerase I poisons in advanced clinical trials.
Continuous efforts in the optimization of indolocarbazoles,
indenoisoquinolines, or benzimidazoles will hopefully lead to
effective candidates for clinical development but the need for new
series of topoisomerase I poisons remains pressing. Our
successful attempts at discovering three series of potent
topoisomerase I poisons: lactone-modified camptothecins,
glycosyl indolocarbazoles and very recently a new series of marine
products, will be presented. In antitumor pharmacology but also
in the field of infectious diseases, topoisomerase I remains an
actively studied protein which can be targeted via its well known
DNA cleavage activity and/or its newly identified kinase activity.
1.  Bailly, C. (2003) Homocamptothecins: potent topoisomerase I inhibitors
and promising anticancer drugs. Crit. Rev. Oncol. Hematol. 45, 91-108. 
2.  Bailly, C. (2003) Targeting DNA and topoisomerase I with indolocarbazole
antitumor agents. In “Small Molecule DNA and RNA Binders”, Vol. 2, Eds:
Demeunynck M, Bailly C., Wilson WD., Wiley-VCH, pp. 538-575. 
S4
PATTERN RECOGNITION AND GRID COMPUTING IN 
DRUG DISCOVERY
W Graham Richards, Department of Chemistry, University of 
Oxford 
The completion of the sequencing of the human genome is being
followed by massive investment in producing crystal structures of
proteins. Many of these may be targets for anti-cancer drugs. We
have developed pattern recognition techniques to find the binding
sites on proteins of known structure. 
It is then possible to do virtual screening using computational
methods. Grid computing where this task is distributed over many
machines provides massive power for very extensive searches. By
adopting screen saver technology we have reached a stage where
we have over two million personal computers performing this task
in over 200 countries. This has  provided over 200,000 years of
CPU time, permitting the screening of some 3.5 billion drug-like
molecules against the following protein targets: superoxide
dismutase; vascular endothelin growth factor; cyclooxygenase;
tyrosine kinase; ras; insulin tyrosine kinase; fibroblast growth
factor receptor; CDK-2; protein-tyrosine-phosphatase; farnesyltrans-
ferase; raf and VEGFr1. 
Fuller details can be found at ww.chem.ox.ac.uk/curecancer.html
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DRUGS THAT TARGET TUMOUR HYPOXIA: THE PROMISE
AND THE CHALLENGE
William A Denny
Auckland Cancer Society Research Centre, Faculty of Medical &
Health Sciences, The University of Auckland, Private Bag 92019,
Auckland, New Zealand 
Tumour hypoxia resulting from inefficient blood vessel networks
in growing solid tumours is a widespread phenomenon, with about
65% of all human tumours surveyed containing >35% of hypoxic
cells. These cells are resistant to radiotherapy and some
chemotherapeutic drugs, and up-regulate a variety of survival
genes. Although such hypoxia is essentially restricted to solid
tumour tissue, and can thus be potentially exploited for selective
chemotherapy, this has not proved easy. Four main classes of
hypoxia-activated (bioreductive) prodrugs have been described;
quinones, nitroaromatic mustards, aliphatic N-oxides and aromatic
N-oxides. In the latter category is tirapazamine, which is currently
in Phase III trials, and is expected to become the first hypoxia-
activated prodrug registered for clinical use.  
Experience with each of these classes has revealed necessary
design requirements for such prodrugs. These include efficient
extravascular diffusion of the prodrug to hypoxic regions, efficient
and selective activation to a toxic activated species (effector) by
the small proportion of hypoxic cells present, and efficient (albeit
controlled) diffusion of the effector to kill surrounding non-
hypoxic tumour cells. The latter is governed both by the stability
(life-time) of the effector and its lipophilicity.
Measuring these properties, and using the quantitative data
generated to design improved prodrugs, will be illustrated by
recent work in our laboratory with both nitroaromatic mustards
and aromatic N-oxides (analogues of tirapazamine). 
S6 
Understanding how anti-CD20 monoclonal antibodies work.
(Bournemouth July 03) 
Martin Glennie, Suzanne Morgan, Claude Chan, Ruth French,
Alison Tutt, Peter Johnson and Mark Cragg
Of all the ‘naked’ anti-cancer antibodies that have been
investigated to date, those directed at CD20 on B-cell lymphoma
appear to be the most active.  However, it is still unclear which
effector functions are responsible for this potency.  CD20 mAb are
unusual in that they are capable of mediating multiple effector
functions, including antibody dependent cellular cytotoxicity
(ADCC), complement dependent cytotoxicity (CDC), and direct
transmembrane signalling for apoptosis.  Since their ability to
induce apoptosis is one of the features that distinguishes them from
most other anti-lymphoma mAb, it is generally felt that this
property is probably important in vivo.  However, it is equally
plausible that in vivo activity relies on a combination of effector
functions, including the ability to generate an as yet undefined
active immune response which may take months to acquire.   
We have recently investigated the effector functions of an
extended panel of anti-CD20 mAb.  Whilst they all mediate ADCC
provided they are of the correct isotype, we find that they can be
divided into two very distinct sub-groups based on their ability to
mediate CDC.  Type 1 anti-CD20 mAb, designated Rituximab-
like, are highly active in CDC, whilst type 2, designated B1-like
are almost completely inactive. The two sub-types appear to be
directly determined by the readiness with which they translocate
CD20 into lipid ‘rafts’. Interestingly, although poor at CDC, the
B1-type mAb are generally more potent at apoptosis.  
S8 S7
CELLULAR THERAPIES FOR LEUKEMIA AND LYMPHOMA 
Malcolm K. Brenner,  Center for Cell and Gene Therapy, 
Baylor College of Medicine, Houston, Texas USA 
The success of monoclonal antibody therapies for leukemia and lymphoma
has invigorated efforts to use the immune system to eradicate these diseases,
in the hope that the greater specificity of the system will produce fewer adverse
effects than conventional small molecule therapeutics. The ability of donor
lymphocyte infusions to eradicate residual host chronic myeloid leukemia
(and with lesser frequency AML, lymphoma and myeloma) after allogeneic
stem cell transplantation has increased optimism that cellular as well as humoral
immune mechanisms may be usefully applied to disease treatment. The field 
engineering and gene transfer, which allow the specificity and function of the
potential effector cells to be enhanced.  
In this presentation I will describe pre-clinical and clinical results for three of
major approaches currently in use for leukemia and lymphoma. First is the
active immunotherapy, in which there is local injection of leukemia or
lymphoma cells expressing immunostimulatory genes that trigger a systemic
cell mediated immune response against weak or tolerizing tumor associated 
antigens. This approach is currently being studied in patients with ALL, AML
and CLL. Second is the adoptive transfer of tumor antigen specific T cells, an
approach we are currently studying in EBV associated malignancies including
Hodgkin Disease and Nasopharyngeal cancer. Finally, we are developing
chimeric receptor expressing T cells that are specific for tumor associated anti- 
such as EBV via their native receptor. These chimeric EBV specific T cells re-
ceive multiple co-stimulatory signals when they engage their native target which
enhances their activity against the malignant target recognized through their
chimeric receptor.
  These approaches are promising in terms of the immunologic and antitum or
responses they produce, and are cost competitive with small molecule based the-
rapies. However, their eventual widespread implementation into clinical practice
will require a reallocation of resources by the pharmaceutical industry and by
medical institutions towards cellular manufacturing and away from drug develop
ment and purchase. How easy it will be to effect such a change remains to be seen
has also been encouraged by recent technological improvements in molecular
gens (such as CD19) via their chimeric receptor, and for persistent viral antigens
DNA VACCINATION IN B CELL MALIGNANCIES AND 
SOLID TUMOURS 
Christian Ottensmeier, Cancer Sciences Division, University of 
Southampton. 
Our improved understanding of the human immune system now
allows us to to design rational immunological treatment strategies
in the laboratory and to assess their effect in clinical trials.  DNA
vaccination can be used as a platform technology for the induction
of specific anti-tumour immunity.  So far our vaccines have been
patient specific and encode the tumour derived immunoglobulin
heavy and light chain variable region genes in a single chain
format (scFv).  In order to promote immunity the scFv is linked to
a strongly immunostimulatory sequence from fragment C of
tetanus toxin (FrC).  The vaccine backbone is a plasmid cassette
which additionally contains CpG motifs as unspecific immune
enhancers. 
This vaccine design is being tested in a series of tightly focussed
phase I/II clinical trials.  The first trial in three centres investigates
patients with follicular lymphoma (FL).  Consistent induction of
immunity against FrC and in some patients against the tumour
derived immunoglobulin can be detected.  In a parallel study
donors of allografts are vaccinated against their siblings’
myeloma.  Early data suggests induction of significant anti-
idiotypic responses.
In solid tumours, anti-tumour immunity requires the induction of
CD8+ T cells.  In murine system this can be achieved with a
modified vaccine design which induces high levels of epitope-
specific T cells.  These can protect against tumour challenge and
act therapeutically.  This novel design is now undergoing testing
in patients and if successful opens the opportunity of designer
vaccination against a wide variety of solid tumour antigens. 
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DENDRITIC CELL BIOLOGY AND POTENTIAL 
APPLICATIONS IN CANCER THERAPY.
Ingo Schmidt-Wolf, Medizinische Klinik und Poliklinik I, 
University of Bonn, Germany
Dendritic cells (DC) play a major role in the generation of immunity against 
tumour cells. DC can be grown under various culture conditions, which 
influence the phenotypical and functional properties of dendritic cells and 
there by the consecutive immune response mainly executed by T cells. 
Antigen receptors (TCR) of tumour-specific T cells recognise tumour-
associated peptides that are presented in the context of HLA class-I or class-
II molecules by the APC. Successful recognition of tumour-antigen by the 
T-cell is not only dependent on TCR-peptide-HLA-interaction, but other co-
stimulatory signals must be provided to prevent anergy. These are mainly 
CD80/CD86-CD28- or CD40-CD40L-interactions. These interactions do not 
only underline the importance of T cells, but also the significant role of 
dendritic cells (DC), which are the most potent antigen-presenting cells 
among others like monocytes, macrophages and B cells. Several in vitro and 
in vivo studies showed the ability of vaccination with DC to elicit tumour-
specific T-cell immunity. This result emplies that (1) DC might be just 
another altered element of the immune system or (2) DC are able to 
overcome tumour-protective alterations in cancer patients by inducing 
effective CTL response or (3) both. In this context a phenotypic and 
functional dichotomy of DC in DC1 and DC2 appears to be of importance. 
DC1and DC2 cells were found to produce different cytokines and there by 
induce TH1 and TH2 differentiation, respectively. The lymphoid-related DC 
(DC2) are CD11c- and have been shown to induce a tolerating response 
versus tumour cells by activating mainly TH2 cells, whereas myeloid-
derived DC (DC1) are immunostimulatory via TH1 cells. Various 
conditions, which are important during generation and administration of 
dendritic cells to elicit a tumouricidal T cell-based immune response will be 
discussed. 
S10 
CHROMOSOMAL TRANSLOCATIONS, FUSIONS GENES
AND ACUTE LEUKAEMIA
Vaskar Saha, Cancer Research UK, Children’s Cancer Group, 
London, Barts and The London E1M 7BQ 
The acute leukaemias of childhood are characterised by specific
non-random chromosomal translocations. These translocations occur 
as a result of chromosomal breakages and illegitimate repair and these 
events tend to occur early in life and often inutero. Translocation 
breakpoints occur at genomic hotspots and target genes, which are 
either transcription factors or tyrosinekinases. The genes appear to be 
part of a regulatory network that functions via chromatin mediated 
pathways in determining the development of a haematopoietic cell in a 
hierarchical fashion. Mostly translocations result in an in-frame fusion 
of the targeted genes to produce a chimaeric oncogene. It is thought 
that the chimaeric product dictates aberrant haematopoiesis and an 
arrest in differentiation. In parallel to the clinical situation, mice 
transgenic for these fusions develop leukaemia after a period of time. 
Moreover it is apparent that translocations can be detected in many 
more children than go on to develop disease. Thus while the fusion 
product initiates leukaemogenesis, other changes are necessary for 
disease to manifest. These secondary genetic events are currently not 
well characterised and transgenic models will play an important role 
in unraveling the sequence of events. An increase in the understanding 
of the nature of the fusion product and the regulatory pathways 
involved will in due course allow critical molecules to be targeted by 
novel therapeutic agents.  Tyrosinekinase and histone deacetylase 
inhibitors are already in clinical trials and other molecules will follow. 
Within the understanding of leukaemogenesis lies a revolution in 
leukaemia therapy.
S11 
PHARMACOGENOMICS OF HUMAN CANCER: CHILDHOOD 
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AS A PARADIGM 
William E. Evans, on behalf of collaborators at St. Jude Children’s 
Research Hospital, Memphis, TN, USA and Sophia Children’s Hospital, 
Rotterdam, The Netherlands. 
Acute lymphoblastic leukemia (ALL) comprises a number of genetic subtypes 
that are created by non-random chromosomal translocations producing aberrant 
gene fusions, with specific genetic subtypes having significantly different 
prognoses (Pui and Evans, NEJM, 1998). We have shown that the pattern of 
gene expression in ALL blasts, prior to treatment, discriminates among the 
major genetic and lineage subtypes of childhood ALL, and that gene expression 
profiles (U95A) are able to identify patients who have a high risk of treatment 
failure (Yeoh et al, Cancer Cell, 2002). More recently, we have taken a genome-
wide approach (U95A) to determine whether there are non-random changes in 
gene expression following treatment with individual antileukemic agents or 
combinations, and whether gene expression differs according to the specific 
treatment given. This has revealed distinct treatment-specific changes in gene 
expression after in vivo exposure to anticancer agents, and established that 
leukemia cells of different genetic or lineage subtypes, share common pathways 
of genomic response to the same medications. Further, these studies have shown 
that treatment-induced changes in gene expression when the drug combination 
(HDMTX + MP) was given to treat ALL, differed markedly from the composite 
of the two agents when given alone (only 14% of genes that changed after single 
agents changed at the combination). To assess genomic determinants of the 
intracellular disposition of antileukemic agents, we have identified gene 
expression profiles (U95A) that discriminate the level of intracellular 
accumulation of methotrexate polyglutamates (MTXPG) after in vivo high-dose 
MTX treatment. Finally, we have used gene expression profiling  (U133A) of 
leukemia cells to identify genes that discriminate ALL cells that exhibit in vitro 
sensitivity versus resistance (lowest third versus highest third for LC50 in MTT 
assay) to L-asparaginase, daunorubicin, and prednisolone, whereas vincristine 
sensitivity could not be discriminated. Collectively,these studies and those by 
others, illustrate the potential of gene expression profiling of primary cancer 
cells to illuminate genomic determinants of treatment response.  
S12 
CML IN CHILDREN: MOLECULAR THERAPY VS MYELOABLATION
IRENE ROBERTS, IMPERIAL COLLEGE LONDON
Chronic myeloid leukaemia (CML) constitutes 2-3% of leukaemias in 
childhood with a prevalence of 1:100,000. The molecular basis, as in 
adults, involves a reciprocal translocation, t(9;22)(q34;q11), forming a 
BCR-ABL fusion gene & protein with constitutive tyrosine kinase 
activity. Management of childhood CML is directed by its triphasic 
nature: treatment response is optimal in chronic phase (CP) (median 
duration 4y); less good in accelerated phase (AP) (duration 6-12m); & 
poor in blast crisis (BC) (duration 3-6m). Current strategies for 
management require a choice between two radically different approaches 
and for children not only are the aims of treatment often different from 
adults, but there are also few data to inform this choice. The first option, 
stem cell transplantation (SCT) offers a high rate of long-term cure at the 
expense of significant mortality/morbidity. The second option, 'molecular' 
therapy with the tyrosine kinase inhibitor, imatinib, induces a high 
cytogenetic response rate with minimal morbidity but an unknown, and 
probably very low, chance of long-term cure. For children in CP the 
treatment of choice is SCT from an HLA-identical sibling donor (sibD) or 
fully matched volunteer unrelated donor (VUD). Recent data indicate 
overall 3-5y survival/predicted cure of >70% for sibD & 60% for VUD. 
Treatment of choice for children in AP or BC is SCT as soon as possible 
using the best available donor (mis-matched/haplo-identical donors if 
necessary) since the risk of treatment-resistance is high. Imatinib may be 
used in AP or myeloid BC to achieve temporary control, with SCT carried 
out as soon as evidence of imatinib-resistance is detected since this 
usually heralds rapidly transforming disease. This is an exciting time to 
be caring for children with CML. National studies of the natural history of 
childhood CML have been set up to investigate its aetiology in children & 
develop prognostic scores to guide therapy. Molecular monitoring post-
SCT with early donor lymphocyte infusion (DLI) also offers the promise 
of improved long-term results & data from adult trials of imatinib & 
novel agents should help define the role of such innovative therapy in 
children.  
Invited Papers
S3
British Journal of Cancer (2003) 88(Suppl 1), S1–S8 & 2003 Cancer Research UKS13 
MRD IN CHILDHOOD ALL:  HYPE OR HOPE.  
Nick Goulden University of Bristol and Bristol Children’s
Hospital. 
It is now more than a decade since techniques capable of
detection of minimal residual disease (MRD) in childhood ALL
were first described. Design flaws in retrospective studies dashed
early optimism that clinical application of these techniques
would lead to more accurate stratification of treatment. Gradually
these problems have been overcome by technical innovation and
the study of large homogeneous cohorts of patients with
prolonged follow-up. There is now good evidence that clearance
of MRD early in therapy is an independent prognostic factor
within clinically homogeneous cohorts of children undergoing
identical therapy. Consequently most of the major treatment
consortia, including the UK Childhood Leukaemia working party
have adopted MRD based stratification of therapy in frontline
ALL protocols.  
This presentation will focus on four main areas that must be
addressed if the full potential of this technology is to be realised.
First, it is important to note that the clinical significance of MRD
at a given time point is dependent on the method employed to
measure disease and the treatment protocol.  Second, integration
into clinical protocols requires standardised sampling, robust
transport and quality assurance. Third as MRD technology is
relatively expensive, and its benefit will only be seen after a
number of years of follow up, long term funding will be required.
Finally, it is vital that clinicians have realistic expectations of the
benefits of MRD analysis. This is only one step in progress
toward the ultimate therapeutic goal of cure of the greatest
number of patients with minimal toxicity. Novel treatments
tested in large international studies are also integral to this aim.
S14 
TARGETING THE INVASIVE BEHAVIOUR OF MALIGNANT
TUMOUR CELLS 
Ian R Hart, Richard Dimbleby Department of Cancer Research/Cancer Research
UK Laboratory, Rayne Institute, St. Thomas’ Hospital, Lambeth
Palace Road, London SE1 7EH. 
Invasion, the violation of normal tissue boundaries as a consequence of 
deranged sorting of cell populations, is an integral component of the malignant 
phenotype. Presumably invasive behaviour up- or down-regulation of different 
genes, including those encoding cell adhesion receptors and proteolytic 
enzymes.  To identify additional genes contributing to this phenotype we 
compared gene expression levels between the periphery and the centre of breast 
cancers using a combination of microdissection and microarray analysis.  We 
showed that changes in gene expression, associated with minimal variation in 
microanatomical location of neoplastic cells, can be detected within even small 
tumour foci and that these fluctuations in gene expression levels contribute to 
invasive behaviour. While this search for novel genes involved in tumour 
progression is important we already know many of the “players” in this process.  
Polarised cell movement is a necessary component of tumour cell infiltration so 
that interference with the motility machinery could offer a way of significantly 
modifying invasive behaviour. Integrin hetrodimers, expressed at the tumour 
cell surface, play a major role in determining invasion.  Thus we have shown 
that the C-terminal 11 amino acids of the β6-subunit are essential for mediation 
of αvβ6-dependent invasion by oral squamous cell carcinomas.  Abrogation of 
invasive activity of such tumour cells was achieved by intracellular delivery of 
the corresponding sequence of 11aa, either as membrane-permeable chimeric 
peptides or introduced as a minigene by retroviral transduction.  Similar changes 
in human breast cancer cell migration epidermal growth factor (EGF)-induced 
chemotaxis, were achieved using comparable techniques to target the Protein 
kinase Cα(PKCα)-binding sequence of the β1-integrin subunit.  Together these 
findings demonstrate that the exogenous, or retrovirally-mediated, delivery of 
peptides targeted to specific regions of integrin cytoplasmic tails may provide a 
novel method for developing anti-invasive therapies.
These studies also suggest that identification of alterations in integrin levels, an 
understanding of the irinteractions with co-localising proteins and the targeting 
of specific sites within these molecules all offer ways of reducing the potential 
of malignant cells to violate normal tissue boundaries. 
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TRANSCRIPTION OF NEURONAL GENES IN LUNG CANCER 
Judy M. Coulson*,  Physiological Laboratory, The University of 
Liverpool 
Lung cancer continues to be the commonest fatal malignancy in the 
developed world and is the biggest cancer killer in the UK. Lung cancers 
are broadly classified as small cell lung cancer (SCLC) or non-small cell 
lung cancer (NSCLC).  SCLC is aggressive in nature and accounts for 
around 20% of lung cancers, it is distinguished from NSCLC by 
expression of both epithelial and neuroendocrine markers, including 
many neuropeptides. Our studies into transcriptional regulation of the 
neuropeptide arginine vasopressin (AVP) in SCLC identified several 
regulatory motifs in the proximal promoter that bind two classes of 
transcription factor, neurone restrictive silencer factor (NRSF/REST) and 
upstream stimulatory factors (USF-1 & USF-2) (reviewed in Coulson, 
2002, Prog Brain Res, 139: 329). such transcription factors and the 
downstream genes they regulate may represent valuable SCLC-specific 
markers or therapeutic targets.    Although  USF factors were regarded as 
ubiquitous, we have shown differential expression of USF-2 in lung 
cancer types and overexpression of USF-2 in NSCLC activated the AVP 
promoter reporter gene constructs via canonical and non-canonical E-box 
motifs (Coulson et al, 2003, Biochem J, 369, 549).  Other gene promoters 
with USF binding sites show similar regulation patterns in lung cancer 
cell lines.  In contrast, the transcriptional repressor NRSF was regarded as 
restricted to non-neuronal cells, but isoforms have recently been 
identified in both neuronal cells and in SCLC (Coulson et al, 2000, 
Cancer Res, 60, 1840). Experimental evidence suggests that NRSF 
isoforms dysregulate repressor function and we have shown that several 
NRSE-regulated genes are differentially expressed in SCLC and NSCLC.  
Our current research program includes targeting NRSF isoforms with 
inhibitory RNA; candidate gene, proteomic and DNA microarray 
analyses; and validation in clinical samples. 
S16 
GENE ICE AS APPLIED TO STUDIES OF HORMONALLY-
RESPONSIVE CANCERS 
Danish Mazhar*, Simak Ali, Laki Buluwela, Jonathan Waxman and R.
Charles Coombes, Dept of Clinical Oncology, Hammersmith Hospital,
Ducane road, London W12 OHS 
 Breast cancer growth is dependent on oestrogens acting via the oestrogen 
receptor (ER). Prostate cancer provides an equivalent model of hormone-
responsive malignancy in men, with growth of tumours being driven by 
androgens acting at the androgenreceptor (AR). Treatment of both diseases is 
limited by the development of hormone independence. A novel strategy for 
silencing genes by targeting histone deacetylation has been developed. In the 
case of ER- and AR-regulated genes, this has been achieved by fusing ER and 
AR with the transcriptional repressor PLZF to create the hybrid molecules 
PLZF-ER and PLZF-AR. Specific repression of both reporter and genomically 
encoded genes has been shown. This technology, termed Gene Inactivation by 
Chromatin Engineering ("GeneICE"), provides a molecular form of "anti-
oestrogen or -androgen" genetherapy, with the potential advantage of 
switching off ER- andAR-regulated genes in an irreversible way, overcoming 
the problem of acquired "resistance". 
 We have shown that PLZF-ER, when stably transfected into the ER-
expressing cell line, MCF-7, causes repression of endogenous oestrogen-
regulated gene expression and cell growth arrest inculture. In female nude 
mice implanted with 60-day release oestradiol pellets, subcutaneous injection 
of MCF-7 cells transfected with PLZF-ER resulted in no tumour formation in 
12/12 compared with 6/12 mice in the control group injected with the parent 
MCF-7 Tet Off cell line. In similar studies, PLZF-AR has been tranduced into 
the androgen-responsive prostate cancer cell line, LNCaP. The resulting cells 
show an inhibition of androgen-regulatedexpression of Prostate Serum 
Antigen (PSA).     
 These results provide evidence ofthe potential of Gene ICE to silence ER- and 
AR-regulated genes in a specific manner. Moreover, it has been shown that 
breast cancer cell growth in vitro and in vivo can be potently inhibited.  We 
believe that this technology could be used to develop new therapies in breast 
and prostate cancer.
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CELLULAR SENESCENCE -- IMPLICATIONS FOR 
CANCER PROGRESSION 
Judith Campisi, Lawrence Berkeley National Laboratory, 1
Cyclotron Road, Berkeley, CA  94720 USA; and Buck Institute
for Age Research, 8001 Redwood Blvd., Novato, CA 94945 
Normal cells can respond to potential cancer-causing stimuli by
undergoing cellular senescence, a state characterized by an
essentially irreversible arrest of cell proliferation and often
striking changes in cellular function.  Several lines of evidence
support the idea that the senescence response is an important
tumor suppressor mechanism in mammals.  Recent evidence,
however, suggests that cellular senescence is also an example of
evolutionary antagonistic pleiotropy.  Accordingly, these data
suggest that while cellular senescence protects organisms from
cancer early in life, later in life it can promote aging phenotypes,
including late life cancer.  We have found that senescent human
stromal cells can promote the neoplastic progression of
premalignant epithelial cells in culture and in vivo.  These
findings raise the possibility of developing novel strategies for
cancer prevention -- strategies aimed a eliminating or reversing
the deleterious effects of senescent cells.  We are currently
determining the molecular pathways by which senescent cells
acquire their altered pro-carcinogenic phenotypes, and
developing tools for reversing the senescent phenotype and/or
selectively eliminating senescent cells.    
S18 
TELOMERASE, CELL MORTALITY AND GRN163, A POTENT AND
SPECIFIC TELOMERASE INHIBITOR FOR CANCER THERAPY 
Calvin B. Harley, Geron Corporation, Menlo Park, CA, 94025 
Telomerase is an enzyme required for maintenance of telomeric DNA
“capping” the ends of eukaryotic chromosomes. It is a unique
ribonucleoprotein reverse transcriptase for which no redundant enzyme nor
efficient alternative pathway is known. Without telomerase, telomeres
shorten to a critical length, chromosomes become unstable, and cell cycle
arrest or death ensues. Human telomerase is tightly repressed in most normal
somatic cells, transiently inducible in certain stem or progenitor cells, and
constitutively activated in germline and tumor cells. Multiple academic
groups and biotechnology and pharmaceutical companies have targeted
telomeres or telomerase for potential therapeutic products over the past 5-10
years. Although there are thousands of publications, including a number of
positive cell- and animal-based efficacy studies, currently there are only a
small number of drug candidates in development. The first clinical studies
based upon telomerase target the catalytic protein component (hTERT) as an
antigen for therapeutic vaccines against cancer, and show preliminary safety
and some signs of efficacy. We are now in IND-enabling development of
GRN163, a highly potent and specific N3’-P5’ thio-phosphoramidate
oligonucleotide inhibitor of telomerase. GRN163 tightly binds to the
template region of the RNA component of telomerase, hTR, blocking the
active site of the enzyme. GRN163 inhibits telomerase activity and prevents
tumor cell growth in culture and in vivo in multiple model systems, with few
if any signs of toxicity to normal cells or tissue. The effects of GRN163 on
tumor growth are generally more rapid in cancer cells with short telomeres,
and may be augmented when used in conjunction with cytotoxic or DNA
damaging agents. In conclusion, the data suggest that GRN163 has the
potential to be a universal anti-cancer agent with acceptable toxicity. 
S19 
G-QUADRUPLEX FORMATION AT TELOMERE ENDS: 
A STRATEGY FOR SELECTIVE INTERFERENCE WITH 
TELOMERE MAINTENANCE IN TUMOUR CELLS
Stephen Neidle, Cancer Research UK Biomolecular Structure Group 
The School of Pharmacy, University of London, UK 
The G-rich telomeric DNA sequences of eukaryotic chromosomes are
involved in a nucleoprotein complex that protects these ends from
degradation and recombination. They are also maintained in length in
almost all cancer cells by the action of the reverse transcriptase
enzyme telomerase, whose catalytic sub-unit is not expressed in
normal somatic cells. Telomerase catalyses the addition of further
telomeric DNA repeats onto the extreme 3' end of the telomere, and
also caps the end. Inhibition of the catalytic function of telomerase has
been shown to result in progressive telomere shortening, leading to
eventual replicative senescence and cell death. However this requires a
long lag time, dependent on initial telomere length. An alternative
strategy focuses on telomeric DNA, and uses small molecules to
induce it to fold into higher-order G-quadruplex structures. We
suggest that this has a dual effect, of (i) inhibiting the catalytic activity
of telomerase, and (ii) hindering telomerase and other proteins from
capping and protecting the 3' ends, thus enabling the rapid onset of
senescence. 
A family of tri-substituted acridine-based small molecule G-
quadruplex interactive molecules, have been developed by us, utilising
structure-based design principles. The most active molecules in this
series inhibit telomerase at 18nM and result in telomere shortening in
several tumour cell lines after long-term treatment. They also rapidly
produce senescence and demonstrate anti-cancer activity in vivo with
cell lines and tumour models that have relatively short telomeres at the
outset. The presentation will review the quadruplex approach, and
discuss its therapeutic potential. 
S20 
TELOMERASE-DIRECTED GENE THERAPY 
W. Nicol Keith, Cancer Research UK Department of Medical 
Oncology, University of Glasgow, Cancer Research UK Beatson
Laboratories, Glasgow G61 1BD, UK. n.keith@beatson.gla.ac.uk
Suicide gene therapy aims to selectively target cancer cell without
harming normal cells thus reducing the toxicity often associated
with conventional therapies. In order to achieve this selectivity,
gene therapy approaches require mechanisms to regulate and limit
the expression of therapeutic genes to cancer cells.  Achieving this
aim remains a challenge for the development of clinically useful
suicide gene therapy.  Tumour-specific gene promoters can be
used for transcriptional targeting to improve selectivity and
increase therapeutic index.  However until recently this has been
difficult and disappointing as many tumour specific promoters
show weak transcriptional activity and are unable to drive efficient
expression of the therapeutic gene. In addition, the promoter
activity is often restricted to one tumour type for example
HER2/NEU positive is limited to use with breast cancer.  As a
solution we have developed the telomerase hTR and hTERT
promoters as highly efficient, cancer specific transcriptional
regulators capable of targeting suicide gene therapy constructs to a
broad range of cancer types. Proof of concept has been achieved
using telomerase targeted adenoviral suicide gene therapy vectors,
using the promoter sequences to regulate expression of the
bacterial NTR gene within a replication defective adenoviral
delivery system.  In-vitro / In-vivo data demonstrates the benefits
of these telomerase vectors to effectively regulate the expression
of genes to activate cytotoxic compounds in cancer cells and not
normal cells.  In all our studies the hTR promoter out performs the
hTERT promoter suggesting that the hTR is the preferred
candidate for therapeutic development. Web Review:  Telomerase-
Directed Molecular Therapeutics. Expert Reviews in Molecular
Medicine, http://www.expertreviews.org/02004507h.htm
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S22 
TARGETED RADIOTHERAPY OF BRAIN TUMOURS 
Michael R. Zalutsky, Department of Radiology, Duke University 
Medical Center, Durham, NC USA. 
External beam radiation therapy is rarely curative for gliomas and 
other central nervous system malignancies due to its lack of tumor 
specificity. Moreover, external beam radiation generally results in 
damage to adjacent normal tissues, compromising neurologic 
function and quality of life in the few patients who do survive. 
Targeted radiotherapy is an attractive alternative treatment strategy 
that utilizes a molecular vehicle such as a monoclonal antibody 
(mAb) to selectively deliver radionuclides to tumour cells. 
Radionuclides that emit α-particles such as 7.2-h half-life 
211At 
(astatine) offer the possibility of combining cell-specific molecular 
targeting with radiation having range of only a few cell diameters. 
Furthermore,  α-particles are considerably more cytotoxic that 
conventional radiation and their effectiveness is independent of 
dose rate and oxygen.  Currently, we are performing a Phase I trial 
evaluating 
211At-labeled human-mouse chimeric anti-tenascin 
81C6 mAb administered into surgically created tumour resection 
cavities in recurrent glioma patients.  Astatine-211 was produced 
at the Duke University Medical Center cyclotron and mAb 81C6 
was labeled with preservation of immunoreactivity using N-
succinimidyl 3-[
211At]astatobenzoate. Seventeen patients including 
13 with glioblastoma multiforme received 10 mg of mAb labeled 
with escalating activities (2-10 mCi) of
211At.  Retention of 
activity in the resection cavity was excellent with less than 0.2% of 
the injected dose found in the blood pool.  Median survival in 
these recurrent brain tumour patients was 60 weeks, and 3 patients 
including 2 with glioblastoma multiforme survived for 3 years. 
We are currently performing preclinical studies to evaluate the 
potential of other 
211At-labeled compounds for the targeted 
radiotherapy of brain tumors.   
S23 
ONCOLYTIC VIRUS THERAPY FOR BRAIN TUMOURS 
Roy Rampling 
Professor of Neuro-oncology, University of Glasgow 
Oncolytic viruses have the ability selectively to replicate in cancercells, thereby 
causing cell lysis and death. They do not rely onadditional agents to effect 
tumour kill, as in ‘suicide gene therapy’. Such selectivity has required genetic 
modification to existing ‘wild-type’ viruses to render them incapable of 
replication in normal cells. Early examples of such agents frequently involved 
gene substitutionor deletion. They included adenovirus (e.g. Onyx 015), 
Poliovirus(PV1(RIP0)), and Herpes virus (HSV1716). Newer agents such as 
thegene enhanced adenovirus Delta-24 RGD are showing increasing promise.
Malignant gliomas have several potential advantages for oncolyticviral 
development.  They are differentiated from the brain by activereplication, and 
the major gene changes that drive this growth andreplication are increasingly 
understood. Major disadvantages howeverare the inherent heterogeneity of 
gliomas and the difficulties ofdelivery of agents to the brain.
Oncolytic viruses have been evaluated in early clinical trial usingsimple direct 
injection techniques (e.g HSV1716, E1B-). Whilst thesehave been shown to be 
safe, efficacy data beyond anecdotal reports arelacking. Neither has it been 
possible to establish clearly the optimalapplication dose for an agent that is 
potentially self-replicating.HSV 1716 has been shown to be safe when injected 
directly intotumour and in brain adjacent to tumour in doses up to 106 
pfu.Furthermore, examination of tumour following resection has 
shownevidence of viral replication. Plans for a formal efficacy evaluation 
arewell advanced. These results and issues of trial design will bediscussed in 
detail.
We have demonstrated synergy when HSV 1716 is used inconjunction with 
radiation to kill tumour cells. We also have indevelopment second generation 
viruses using the basic HSV1716structure to deliver transgenes to enhance 
tumour kill using a ‘suicide’mechanism. These results will be discussed as will 
the potential for‘continuous enhanced diffusion’ to improve delivery.   
Oncolytic viraltherapy shows promise in the management of malignant glioma.
S24
GENETIC ABNORMALITIES ASSOCIATED WITH 
ASTROCYTOMA PROGRESSION 
V. P. Collins, Koichi Ichimura, Lu Liu, Magnus Backlund
Department of Pathology, University of Cambridge, UK 
Astrocytic tumours have been known to progresswith time to 
moremalignanttumour forms for over a century. We have been studying 190 
astrocytic gliomas (136 glioblastomas (GB), 39 anaplastic astrocytomas (AA) 
and 15 astrocytomas (A)) for abnormalities of genes in the RB1pathway 
(CDKN2A, CDKN2B, CDK4 and RB1), the p53 pathway (p14ARF, MDM2, and 
TP53), as well as PTEN and EGFR. A and AA hadno wild-type TP53 or one 
mutated allele in 67% of cases. Only29% ofthe GB had no wild type TP53with 
an additional 6% having one mutatedallele. Wild type p14ARF was absent from 
38% of GB and a further 8%had amplification and overexpression of MDM2. 
Thus 76% of GB (103/136), 72% of AA (28/39) and 67% of A (10/15) had a 
deregulatedp 53 pathway indicating that this is almost a prerequisite for 
astrocytictumors. Abnormalities of the RB1 pathway occurredin 21% AA and 
67% GB either by mutation/homozygous deletion of RB1, CDKN2A andCDKN 
2B, or amplification of CDK4. This indicates that disruption of the RB1 pathway 
is directly related to as trocytic tumour progression. Amplification of the EGFR 
gene was not observed in A, was unusual in AA (8%) but common in GB (33%). 
Loss of wild type PTEN occurred in one AA (3%) but was very common in GB 
(47%) and could be found together with all combinations of the other genetic 
abnormalities. Survival of patients with GB is typically less than one year, We 
studied whether any of the genetic factors listed above were related to survival 
inGB alone. We found that abnormalities in any of the four genes (CDKN2A, 
CDKN2B,  RB1,  CDK4) codingfor components of the Rb1 pathway were 
associated with shorter survival (p=0.002). In combination with loss of wild-type 
PTEN the association was even stronger (p<0.001), the median post-operative 
survival being 166 days as compared with thegroupwithout these abnormalities 
where the median survival was 437 days. The survival difference remained 
statistically significant in Cox Regression analysis adjusting for age (p=0.012). 
The findings indicate that knowledge of the molecular genetic abnormalities in 
glioblastomas provides important data in assessing individual patients. As further 
advances in our understanding of the molecular genetics and cell biologyof 
gliomas are made, in addition to providing prognostic information, such data 
may also provide targets for innovative therapy in the individual case.
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REGULATION AND FUNCTION OF THE P53 TUMOUR
SUPPRESSOR PROTEIN 
Karen Vousden, Beatson Institute for Cancer Research, 
Switchback Road, Bearsden, Glasgow G61 1BD, UK
p53 plays an important role in preventing tumour development by 
responding to stress signals that are encountered during malignant 
progression. Several responses to p53 have been described, 
including cell cycle arrest, senescence, differentiation and 
apoptosis. Cell type, cell environment and presence of 
cooperating signals can all contribute to the choice of response. 
Also, the ability to induce cell cycle arrest and apoptosis are 
separable functions of p53 that can be controlled independently. 
p53-induced apoptosis is important for tumour suppression, and 
virtually all cancer cells have acquired mechanisms to evade this 
response. In many cancers this is achieved by mutation of p53 
itself, but tumours that retain wild type p53 can show defects in 
the ability to activate p53. Stress-induced activation of p53 
involves stabilization of the p53 protein by inhibition of MDM2, 
the ubiquitin-ligase responsible for targeting p53 for degradation. 
Several mechanisms for the inhibition of MDM2 have been 
described, including down-regulation of MDM2 expression, 
phosphorylation of p53 or MDM2 and the interaction of MDM2 
with small proteins such as p14
ARF. In some cancers failure to 
activate p53 is associated with defects in the ability to inactivate 
MDM2, suggesting that MDM2 inhibitors may allow reactivation 
of p53 in this class of cancers. We have developed a high 
throughput screen to identify small molecules that will inhibit 
MDM2 to allow stabilization and activation of p53 and so, to 
some extent, mimic the function of proteins like p14
ARF. A group 
of related small molecules identified in this screen may have 
utility as therapeutic agents.  
S26 
NEW AGENTS: NEW TRIALS; ARE THE RULES OR 
EXPECTATIONS CHANGING?
Dr George Blackledge, VP, Medical Director of Oncology 
AstraZeneca, Alderley Park, Macclesfield 
There has been an explosion in the number of new potential anti-
cancer targets developed over the past few years and in therapeutic 
modalities directed against them.  The specificity of these targets, and 
the number of tumours and patients in whom they are a primary cause 
of cancer drive has meant that both pre-clinical and clinical assessment 
has been different from conventional anti-cancer chemotherapy drug 
development. 
There is now an emerging body of data concerning the new targetted 
agents.  These agents tend to have a relatively low response rate of 
between 10-20% (there are a few notable exceptions to these where a 
single mutated gene is targetted); they have demonstrated activity in 
advanced disease and evidence of clinical benefit as judged by disease 
symptom improvement, but with one or two exceptions their activity 
in combination with standard cytotoxic chemotherapy has been 
disappointing. 
These observations raise important questions about the future of 
oncology drug development with targetted agents.  Trial design needs 
to be tailored to expectations of outcome and patient or tumour 
selection becomes ever more important for the optimal use of such 
agents.  These new targetted agents do represent a genuinely novel and 
potentially important development for cancer treatment and therefore 
expectations should be managed with these agents and the way in 
which clinical trials are carried out should reflect the available data. 
S27 
DEVELOPING DRUGS FOR CANCER: STRIKING BALANCE 
BETWEEN CLINICAL PRAGMATISM AND SCIENTIFIC 
ALLURE 
 Hilary Calvert, Northern Institute for Cancer Research, University 
of Newcastle upon Tyne 
During the last decade Phase III randomised trials have demonstrated 
survival improvements in several common malignancies resulting from 
the use of new cytotoxic drugs, examples being taxanes in breast and 
ovarian cancer, irinotecan in colorectal cancer and gemcitabine in lung 
cancer.  During the same period the identification of new targets as a 
result of advances in understanding the molecular pathology of 
tumours, coupled with advances in medicinal chemistry and antibody 
technology, has resulted in the availability of a increasing number of 
“targeted” agents interacting with processes controlling tumour growth 
and cell division.  Although some of these, for example trastuzumab 
and imatinib, have been spectacularly successful, others have produced 
disappointing Phase III data. It is accepted that a number abnormalities 
of growth control processes are required to generate most of the 
common malignancies so perhaps not surprising that a single 
therapeutic agent working very specifically on a single target may have 
a minimal effect.  If we can develop the ability to define the lesions 
driving a particular patient’s tumour we would be in a position to select 
an individualised combination appropriate for that patient.  Future 
treatments are likely to be multimodal, utilising traditional cytotoxics 
and targeted agents.  Techniques for treatment individualisation can be 
applied to cytotoxic agents since many of these also have well defined 
cellular targets, blurring the distinction between the two.  One 
multimodal approach being developed in the Northern Institute for 
Cancer Research is to develop inhibitors of DNA repair, specifically of 
poly(ADP-ribose) polymerase (PARP) and DNA protein kinase for use 
in conjunction with chemotherapy and radiotherapy. A Phase I trial ofa 
PARPinhibitor is currently under way.
S28 
IS NEOADJUVANT CHEMOTHERAPY OF BENEFIT IN THE 
TREATMENT OF LOCALLY ADVANCED CERVICAL
CANCER?  JF Tierney MRC Clinical Trials Unit, 222 Euston 
Road, London NW1 2DA, UK. 
Despite the enrolment of more than 3000 women in randomised
trials, the benefits and risks of neoadjuvant chemotherapy in the
treatment of locally advanced cervical cancer remained uncertain.
We carried out a systematic review and meta-analysis of individual
patient data to assess its effect in two comparisons. The first
comparison was of neoadjuvant chemotherapy followed by radical
radiotherapy compared to the same radiotherapy alone. When all
18 trials were considered together, a high level of statistical
heterogeneity suggested that the results could not be combined
indiscriminately. Much of the heterogeneity was explained by
separate analyses of groups of trials. Trials using chemotherapy
cycle lengths shorter than 14 days (HR=0.83, p=0.046) or cisplatin
dose intensities greater than 25mg/m
2per week (HR=0.91, p=0.20)
tended to show an advantage for neoadjuvant chemotherapy on
survival. In contrast, trials using cycle lengths longer than 14 days
(HR=1.25, p=0.005) or cisplatin dose intensities lower than
25mg/m
2  per week (HR=1.35, p=0.002) tended to show a
detrimental effect of neoadjuvant chemotherapy on survival. The
second comparison was of neoadjuvant chemotherapy followed by
surgery compared to radical radiotherapy alone. The combined
results from 5 trials (HR=0.65, p=0.0004) indicated a highly
significant reduction in the risk of death with neoadjuvant
chemotherapy, but there were some differences between trials in
their design and results. Despite some unexplained heterogeneity,
the timing and dose intensity of cisplatin-based neoadjuvant
chemotherapy appears to have an important impact on whether or
not it benefits women with locally advanced cervical cancer and
warrants further exploration.  
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1ST-LINE CHEMOTHERAPY FOR OVARIAN CANCER – CURRENT 
STATUS 
A. du Bois, Dr.-Horst-Schmidt-Kliniken, Wiesbaden, Germany
Platinum-based chemotherapy is the mainstayof systemic treatment of advanced
ovarian cancer. However, details are at least partially contro-versial. Among others, 
the question regarding the impact of combination regimens compared to single agent 
platinum is cause for vital discussion. Until now, no randomised trial has ever shown 
superiority over single agent carboplatin. However, 2 randomised trials have shown 
superiority for cisplatin-paclitaxel (PT) over cisplatin-cyclophosphamide (PC), a 
regimen formerly believed to be at least equivalent with carboplatin. The average 
survival gain in these trials was about 1year (HR 0.7 and 0.75). 3 further trials 
compared PT versus carboplatin-paclitaxel (TC) showing at least comparable activity 
and better tolerance and quality of life for the latter. Based on these results, TC was 
adopted as new standard arm in almost all study groups and randomised trials. 
Questions about the role of platinum-paclitaxel combination chemotherapy have been 
raised when ICON-3 reported no superiorityfor TC compared to single agent carbo-
platin or PAC and GOG # 132 failed to show superiority of PT over single agent 
cisplatin. Both trials are difficult to bring in line with GOG # 111 and OV-10. 
However, both trials reported a considerable cross-over rate in the single agent 
platinum arm (GOG#132 > 50% even before progression; ICON-3 about 40% mainly 
after progression). Furthermore, the designof ICON-3 makes it difficult to compare it 
with other trials (more heterogenous population including FIGO I pts., individual 
choice of standard arm, different randomisation procedures, differences with respect 
to participating countries / studygroups / recruitment numbers per centre, no audit or 
monitoring in contrast to GOG # 111 and OV-10). Moreover, response rates in 
ICON-3 were not reported, neither was a comparison performed between comparable 
subgroups among GOG 111, OV-10,and ICON-3 , although data have been merged 
for a meta-analysis. Last but not least, surgical details of ICON-3 can only be 
interpreted based on the publication and show a rather low percentage of completely 
debulked patients. In summary, neither ICON-3 nor GOG132 have shown superiority 
of any regimen compared to PT/TC, and the meta-analysis of all 4 trials did still show 
benefit for TC. Considering all 4 trials, it cannot be ruled out that at least some pts. 
would benefit from combination therapy. Therefore, TC remained the standard arm as 
chosen by all study groups (including the ICON group). Outside of trials, single agent 
carbo might be an option for pts. not willing to trade a possible benefit for the 
additional taxan associated toxicity – with the option of receiving paclitaxel in case of 
relapse or persisting tumor.
S31 
OVARIAN CANCER: MOLECULAR STRATEGIES FOR A
LOCOREGIONAL PROBLEM  
Hani Gabra 
Cancer Research UK, Edinburgh Cancer Research Centre, Crewe
Road South, Edinburgh, UK 
The natural history of ovarian cancer is characterised by
progression of bulky loco-regional peritoneal dissemination in the
relative absence of visceral metastatic disease. Most patients die
from this dominant clinical scenario. An early lesion for epithelial
ovarian cancer has not been defined, and there is no strong
evidence that early stage ovarian cancer commonly progresses to
advanced stages. These uncertainties coupled with low prevalence
of ovarian cancer in the population present intellectual and
practical difficulties for screening of the disease. Strategies that re-
focus on control of peritoneal dissemination of ovarian cancer
rather than either screening or total eradication of systemic disease
might therefore be expected to improve prognosis. Our
understanding of the relationship between ovarian cancer and the
peritoneum is poor. There are some notable examples of progress,
however. In this talk I will review the relationships between
ovarian epithelial oncogenesis, inflammation, cellular adhesion
and cell death. Evidence from our own work and that of others on
molecules involved in these processes will be presented in order to
develop consistent testable hypotheses for molecular interventions
to control progressive peritoneal dissemination of ovarian cancer. 
S30
PROGRESS IN SCREENING FOR OVARIAN CANCER  
Ian Jacobs, Bart’s and the London, Queen Mary School of Medicine,
London, UK 
Efforts to screen for early OC are based upon the hypothesis that
outcomes will improve if OC is diagnosed and treated whilst
asymptomatic and preclinical. There is good evidence from large
prospective population studies of over 100,000 women that
preclinical OC can be detected by transvaginal ultrasound or by a
multimodal approach using CA 125 as a 1
o test followed by
ultrasound as the 2
o test in selected cases. The available data suggest
that the multimodal approach has a lower false positive rate, whilst
the ultrasound approach may have higher sensitivity. The sensitivity
of the multimodal approach has been improved by use of ‘Risk of
Ovarian Cancer’ (ROC) algorithm to interpret CA125 results which
assesses the pattern of CA 125 over time rather than in relation to a
simple cut off.
On the basis of this progress a major national three arm randomised
control trial involving 200,000 postmenopausal women, called
UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening)
was launched in 2001. The study involves randomisation to a control
arm (100,000), a multimodal arm screened with the ROC algorithm
followed by ultrasound (50,000) and a transvaginal ultrasound arm
(50,000). The primary end point for the study is the impact of
screening on ovarian cancer mortality. In addition UKCTOCS will
assess the issues of target population, compliance, health economics
as well as the physical and psychological morbidity of screening. A
second study is underway to optimise screening in women at high
risk of OC because of a strong family history of cancer (UKFOCSS
– UK Familial Ovarian Cancer Screening Study). When data from
these studies becomes available during the next decade the place of
OC screening in both the high risk and general populations should
be clarified. 
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